About vaccines

A third, booster dose of either the ChAdOx1 nCoV-19 (Oxford-AstraZeneca), BNT162b2 (Pfizer-BioNTech), AD26.COV2-S (Janssen) or CoronaVac (SinoVac) coronavirus vaccine induce a significant increase in antibody levels in those who have previously received two doses of CoronaVac. // 25.1.2022

A new study assesses the effectiveness of two and three doses of the BNT162b2 vaccine against Omicron-related hospitalizations.// 25.1.2022

The current paper compares the effectiveness of two vs. three doses of these vaccines against Omicron compared to Delta. // 25.1.2022

In a new study, researchers assessed the extent and duration of the neutralization of SARS-CoV-2 Omicron variant of concern after the administration of two and three doses of the BNT162b2 mRNA vaccine. // 25.1.2022

// 24.1.2022

In a new study, scientists have recently developed a computational model to predict the antigenicity and immune escape ability of emerging variants of SARS-CoV-2. // 24.1.2022

A new study measured T cell activity in vaccinated individuals and found a third vaccine provided substantial T-cell immunity against the Omicron variant of SARS-CoV-2. // 24.1.2022

Researchers describe the state of adaptive immunity following vaccination with the Pfizer-BioNTech BNT162b2 COVID-19 vaccine. // 23.1.2022

Researchers explore the dynamics of COVID-19 vaccine-induced protection against SARS-CoV-2 variants of concern. // 23.1.2022

We report the antibody neutralization against Omicron SARS-CoV-2 after 2 and 3 doses of BNT162b2 mRNA vaccine. // 22.1.2022

BACKGROUND: Waning of COVID-19 vaccine protection and emergence of SARS-CoV-2 Omicron (B.1.1.529) variant have expedited efforts to scale up booster vaccination. // 21.1.2022

Despite breakthrough infections, a new study shows a COVID-19 vaccine is effective nine months after the first shot. The findings, based on data on 10.6 million North Carolina residents, support use of boosters to provide ongoing prevention of hospitalization and death from COVID-19. // 12.1.2022

Researchers investigated the effectiveness of the SARS-CoV-2 Omicron-variant induced immunity, whether it is cross-protective against other variants, and if earlier infection with the SARS-CoV-2 Delta variant offers protection against Omicron. // 20.1.2022

Researchers present evidence for early community transmission of the SARS-CoV-2 Omicron variant in New Delhi, India. // 20.1.2022

Researchers examine the effects of previous SARS-CoV-2 infections on the immunity offered by SARS-CoV-2 vaccination. // 20.1.2022

A recent study looked at the strength, durability and breadth of neutralizing antibody responses generated by breakthrough infections in individuals vaccinated against SARS-CoV2. // 20.1.2022

A new study revealed an overall high vaccine uptake and significant vaccine effectiveness of BNT162b2 against COVID-19, among healthcare workers in Wales. // 20.1.2022

A new study aimed to understand the risk of COVID-19 infection given certain serological parameters, in a group of vaccinated healthcare workers with high rates of exposure to the virus, followed up at 9 months from vaccination. // 20.1.2022

This report describes COVID-19 cases and hospitalizations by vaccination status and previous COVID-19 diagnosis before and after the Delta variant became predominant. ”In addition, it shows that people who remain unvaccinated are at the greatest risk of hospitalization and death.” // 19.1.2022

This systematic review and meta-analysis investigates the frequency of adverse events in placebo groups compared with that in vaccine groups in COVID-19 vaccine trials. // 18.1.2022

A recent article published in the journal Science explains how SARS-CoV-2 variants can bypass vaccine-induced immune defenses. However, immunity is restorable with a booster shot. The paper's authors outlined the importance of a booster shot in maintaining immunity and preventing severe infection. // 18.1.2022

The authors highlight that they have shown that boosted individuals are significantly more protected against SARS-CoV-2 infection than any other group // 18.1.2022

In a new study, a team of researchers estimated the pre-pandemic incidence rates of adverse events of special interest now observed in association with COVID-19 vaccines in Canada. // 18.1.2022

Researchers have been investigating the vaccine response of healthcare workers from specific vaccines to different variants. // 18.1.2022

New study results posted to the medRxiv* preprint server found that COVID vaccine boosters increase immunity by enhancing T cell immune memory. In the face of the severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) Omicron variant, vaccinated people who had received a third booster shot maintained high T cell responses than people with naturally acquired immunity or vaccine-induced immunity from two doses of the SARS‑CoV‑2 vaccine. // 18.1.2022

In a new study, researchers analyzed the neutralization of SARS-CoV-2 Omicron and D614G variants before and after subjects received COVID-19 booster vaccinations. // 18.1.2022

A recent study examined the question as to whether vaccination protects against Omicron infection by assessing breakthrough infection rates in participants at a superspreader event. // 18.1.2022

A recent study revealed the effectiveness of 93% for the BNT162b2 vaccine against COVID-19 hospitalization among adolescents (12 to 18 years). This study included 179 patients at 19 sites in 16 states. The same group of researchers have extended their analysis to 31 locations in 23 states across the U.S. and recruited 266 more patients who had been hospitalized with SARS-CoV-2 infection. // 13.1.2022

In a new study, a team of researchers determined the impact of the emerging SARS-CoV-2 variants of concern and vaccination status on the SARS-CoV-2 transmission dynamics. // 13.1.2022

Researchers describe the pattern and characteristics of infections after COVID-19 vaccination. // 13.11.2022